RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for Tough-to-Treat leukemia
Disease control OngoingThis early-stage study tests a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in adults with a type of leukemia that has returned or not responded to standard treatment. The main goals are to find the safest dose and identify side effects. Abou…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:09 UTC
-
Promising new combo targets rare infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with chemotherapy for infants and young children with a hard-to-treat leukemia that has returned or not responded to treatment. The drug targets a specific genetic change (KMT2A rearrangement) that drives the cancer. The goal …
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New drug cocktail shows promise against rare leukemia
Disease control OngoingThis early-stage trial tests a combination of the oral drug venetoclax with standard chemotherapy and targeted therapies in adults with a specific, hard-to-treat leukemia (Ph+ ALL) that is either newly diagnosed or has returned. The main goal is to find the safest dose and see ho…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New hope for kids with relapsed leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC